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Objectives: Obesity has been associated with worse postoperative outcomes. No data are available
regarding short-term results after liver resection (LR). The aim of this study was to analyse outcomes in
obese patients (body mass index [BMI] > 30 kg/m2) undergoing LR.
Methods: 85 consecutive obese patients undergoing LR between 1998 and 2008 were matched on a
ratio of 1:2 with 170 non-obese patients. Matching criteria were diagnosis, ASA score, METAVIR fibrosis
score, extent of LR, and Child–Pugh score in patients with cirrhosis.
Results: Operative time, blood loss and blood transfusions were similar in the two groups. Mortality was
2.4% in both groups. Morbidity was significantly higher in the obese group (32.9% vs. 21.2%; P = 0.041).
However, only grade II morbidity was increased in obese patients (14.1% vs. 1.8%; P < 0.001) and this
was mainly related to abdominal wall complications (8.2% vs. 2.4%; P = 0.046). No differences were
encountered in terms of grade III or IV morbidity. The same results were observed in major LR and
cirrhotic patients. When patients were stratified by BMI (<20, 20–25, 25–30 and >30 kg/m2), progressive
increases in overall and infectious morbidity were observed (5.6%, 22.4%, 23.7%, 32.9%, and 5.6%,
11.8%, 14.5%, 18.8%, respectively). Rates of grade III and IV morbidity did not change.
Discussion: Obese patients have increased postoperative morbidity after LR in comparison with non-
obese patients, but this is mainly related to minor abdominal wall complications. Severe morbidity rates
and mortality are similar to those in non-obese patients, even in cirrhosis or after major LR.
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Introduction
The prevalence of obesity is continuously increasing worldwide.1
In the USA more than one-fourth of the population has a body
mass index (BMI) > 30 kg/m2.2 In Europe the situation is less
pronounced, but the incidence of obesity is advancing rapidly and
current prevalences range between 6% and 27%.3 Even in Asia,
obesity is becoming a significant problem.4
Obesity may negatively impact on surgical outcomes through
associated co-morbidities, such as cardiovascular and pulmonary
diseases and diabetes,5,6 and increased technical difficulties.
With respect to liver surgery, obesity may be associated with
liver parenchymal disease such as steatosis and non-alcoholic
fatty liver disease,7,8 which can further increase postoperative
morbidity.7,9–12
Outcomes in obese patients in different surgical fields have
been analysed, but data are controversial. Several studies
have reported no increased risk outside that for minor
complications,13–17 whereas other reports have found obesity to be
associated with high morbidity, mortality and poor longterm
outcomes.18–23 Recently, a large series compared 808 obese with
5528 non-obese patients undergoing elective general surgery and
reported similar morbidity rates between the two groups, except
for wound infections.24 However, few liver resections were
included. At present, no study specifically focuses on liver surgery
in obese patients with a BMI > 30 kg/m2.
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The aim of the present study was to compare outcomes in obese
and non-obese patients undergoing liver surgery in a case–control
setting. Matching was intended to limit confounding factors, such
as co-morbidities and liver function, in order to focus specifically
on the impact of obesity in liver surgery.
Materials and methods
Between January 1998 and July 2008, 719 patients underwent liver
resection at Henri Mondor University Hospital. All patients were
considered for the present study. On the basis of theWorld Health
Organization (WHO) definition of obesity (BMI > 30 kg/m2),1 85
(11.8%) consecutive obese patients were identified. They included
67 (78.8%) patients with class I obesity (BMI 30–35 kg/m2), 13
(15.3%) with class II obesity (35–40 kg/m2), and five (5.9%) with
class III obesity (>40 kg/m2).1 Obese patients were matched at
a ratio of 1:2 with 170 non-obese patients (BMI  30 kg/m2).
Matching criteria were diagnosis (benign vs. malignant, the same
diagnosis whenever possible), American Society of Anesthesiolo-
gists (ASA) score (I, II and III),METAVIR F score for liver fibrosis25
(0–1, 2, 3 and 4), extent of liver resection (major vs. minor hepa-
tectomy) and, in cirrhotic patients (METAVIRF4), theChild–Pugh
score.26 The median BMI was 32.6 kg/m2 (range: 31.0–62.4 kg/m2)
in the obese group and 24.5 kg/m2 (range: 16.9–28.9 kg/m2) in the
non-obese group. The strict matching policy is detailed in Table 1.
Preoperative characteristics, intraoperative data, pathological
results concerning both primary parenchymal disease and the
pathological lesion, and postoperative outcomes were compared
between the two groups. Subgroup analysis of postoperative out-
comes was performed for major liver resections, cirrhotic patients,
diabetic patients and those with moderate or severe steatosis. Cor-
relations between BMI and outcomes were further studied by
stratifying patients by BMI values (<20, 20–25, 25–30 and >30 kg/
m2).Among the obese patients, outcomes according to the severity
of obesity were analysed by stratifying patients according to
obesity classes I (BMI 30–35 kg/m2), II (35–40 kg/m2) and III
(>40 kg/m2).1
Preoperative patient evaluation
Preoperative patient selection systematically relied on liver func-
tion tests, computed tomography (CT) volumetry of the future
liver remnant if major liver resection was planned, and anesthe-
siological evaluation based on case history, physical examination,
biochemistry, arterial blood gas, electrocardiography (ECG) and
chest X-ray. Further evaluations, such as cardiological and pulmo-
nary tests, were required in selected patients only. No specific
preoperative work-up was considered for obese patients. Obesity
per se was never considered as a contraindication for liver surgery.
Liver surgery was contraindicated in patients with poor liver func-
tion, inadequate future liver remnant (even after portal vein
embolization or ligation) and severe co-morbidities that exposed
the patient to unacceptable operative risk (usually corresponding
to ASA score IV patients).
Surgical technique
The surgical techniques for both open and laparoscopic liver
resections have been previously reported.27–30 Indications for the
laparoscopic approach have been detailed elsewhere.29,31 Obesity
has never been considered a contraindication to laparoscopic liver
resection. The laparoscopic approach was primarily considered
for lesions of 5 cm located in the anterolateral segments (seg-
ments II–VI) and requiring limited resection, although a few
major resections were performed. Resection of larger lesions,
those located close to the liver hilus or the hepatocaval junction
and the vast majority of major resections were performed using
the conventional open approach.
Intraoperative ultrasonography was routinely performed to
confirm the number of lesions, their size and their relationship
with the intrahepatic vascular structures. Extrahepatic inflow
and outflow vascular control was regularly performed for
anatomic resections, with ligation and division of appropriate
portal and arterial branches and hepatic veins. Bile duct division
was usually performed during the parenchymal transection. Gen-
erally, a tape was placed around the hepatic pedicle and the inter-
mittent Pringle manoeuvre was used only if significant bleeding
occurred. Total vascular exclusion was considered for lesions
invading the inferior vena cava. In open resections, parenchymal
transection was performed with an ultrasonic dissector (CUSA
Dissectron [Integra Life Sciences Corp., Plainsboro, NJ, USA];
SonoSurg [Olympus Corp., Tokyo, Japan]). In laparoscopic cases,
the harmonic scalpel (Ethicon Endo-Surgery, Inc., Cincinnati,
OH, USA) was used for superficial layers and the ultrasonic dis-
sector for deeper transection. Bipolar forceps with continuous
irrigation were used to divide small vessels, whereas absorbable
clips or ligatures were preferred for larger vessels or bile ducts.
Abdominal drainage was used in right or extended right hepate-
ctomies, but usually omitted in other types of resection.
Definitions
Types of hepatectomy were classified according to Brisbane 2000
terminology.32 Major hepatectomy was defined as the resection of
three or more Couinaud segments. Fibrosis was classified accord-
ing to METAVIR F score.25 Steatosis was estimated as the percent-
age of involved hepatocytes, and was categorized as follows: absent
(0%); mild (1–30%); moderate (31–60%), and severe (>60%).33
Operative mortality was defined as death within 90 days after
surgery or before discharge from hospital. Morbidity included all
postoperative complications and was classified according to the
Clavien classification.34 Liver dysfunction was defined as both pro-
thrombin time (PT) <50% and serum bilirubin level >50 mmol/l
on postoperative day (PoD) 5.35
Statistical analysis
Continuous variables were compared between groups by the
unpaired t-test orMann–WhitneyU-test, as appropriate; categori-
cal variables were compared using the chi-squared test or Fisher’s
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exact test, as appropriate. A P-value <0.050 was considered signifi-
cant for all tests.
Results
Patient characteristics
Demographic data were similar between the two groups except
that the obese patient group included a higher proportion of
females (51.8% [44/85] vs. 33.5% [57/170]; P = 0.005). Associated
co-morbidities, including cardiovascular and pulmonary diseases
and diabetes, were not increased in obese patients. Liver function,
even in patients with cirrhosis, was similar between the two
groups (Table 2).
Parenchymal steatosis was related to BMI: it was very frequent
in obese patients, especially in its moderate (31–60%) and severe
(>60%) forms (23.5% [20/85] vs. 3.5% [6/170], P < 0.001 and
4.7% [4/85] vs. 0.6% [1/170], P = 0.044, respectively).
Intraoperative and pathological data
Laparoscopic resection was attempted in about one-third of
patients in both groups; the rate of conversion to hand assistance
Table 1 Matching criteria
Obese patients
BMI > 30 kg/m2 (n = 85)
Non-obese patients
BMI  30 kg/m2 (n = 170)
Median BMI, kg/m2 (range) 32.6 (31.0–62.4) 24.5 (16.9–28.9)
1 Diagnosis
Malignant lesions 74 (87.1%) 148 (87.1%)
Hepatocellular carcinoma 30 (35.3%) 68 (40.0%)
Peripheral cholangiocarcinoma 7 (8.2%) 3 (1.8%)
Colorectal metastases 25 (29.4%) 60 (35.3%)
Non-colorectal metastases 5 (5.9%) 8 (4.7%)
Hilar cholangiocarcinoma 3 (3.5%) 6 (3.5%)
Gallbladder cancer 2 (2.4%) 3 (1.8%)
Benign lesions 11 (12.9%) 22 (12.9%)
Liver adenoma 5 (5.9%) 6 (3.5%)
Haemangioma 2 (2.4%) 3 (1.8%)
Focal nodular hyperplasia 1 (1.2%) 6 (3.5%)
Other lesions 3 (3.5%) 7 (4.1%)
2 ASA score
I 3 (3.5%) 6 (3.5%)
II 57 (67.1%) 114 (67.1%)
III 25 (29.4%) 50 (29.4%)
3 METAVIR F score for liver fibrosis25
0–1 54 (63.5%) 108 (63.5%)
2 9 (10.6%) 18 (10.6%)
3 5 (5.9%) 10 (5.9%)
4 17 (20.0%) 34 (20.0%)
4 Extent of liver resection
Major hepatectomy 42 (49.4%) 84 (49.4%)
Right hepatectomy  segment I 19 (22.4%) 42 (24.7%)
Right trisectionectomy  segment I 9 (10.6%) 18 (10.6%)
Left hepatectomy  segment I 10 (11.8%) 17 (10.0%)
Left hepatectomy  segment VIII 1 (1.2%) –
Left hepatectomy + segments V–VIII – 1 (0.6%)
Central hepatectomy 3 (3.5%) 6 (3.5%)
5 Child–Pugh class in cirrhotic patients n = 17 n = 34
A 16 32
B 1 2
BMI, body mass index; ASA, American Society of Anesthesiologists
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or laparotomy was not increased in obese patients. Pedicle clamp-
ing was used in similar proportions of patients in the two groups.
Obesity was not associated with increased blood loss, and trans-
fusion rate was low in both groups, at about 5% (4/85 vs. 9/170
patients). Median operative time was longer in obese patients
(210 min vs. 180 min), but the difference was not significant
(Table 3).
In terms of pathological data, no differences were encountered
between the two groups. Median lesion diameter and number
were 40 mm (range: 10–190 mm) and one (range: 1–17) in the
obese group vs. 40 mm (range 5–300 mm) and one (range: 1–13)
in the non-obese group (P = 0.939 and P = 0.235, respectively). In
malignant lesions,median surgical margin and complete resection
rates were similar, 10 mm and 83.8% (62/74) vs. 8 mm and
85.1% (126/148), respectively (P = 0.183 and P = 0.792,
respectively).
Postoperative outcomes
The mortality rate was 2.4% in both groups (i.e. two obese and
four non-obese patients). Causes of death were as follows: three
patients, of whom two had hepatocellular carcinoma (HCC)
(BMI 33.1 kg/m2 and 28.0 kg/m2) and one had a Klatskin tumour
(BMI 25.9 kg/m2), died of liver failure and sepsis on PoDs 11, 20
and 45, respectively; one patient (Klatskin tumour, BMI 32.9 kg/
m2) had Roux-en-Y jejunal necrosis and died of sepsis on PoD 28;
one patient (HCC, BMI 26.1 kg/m2) had liver failure secondary to
portal vein thrombosis and died on PoD 29 after an operative
attempt at thrombectomy, and one patient (HCC, BMI 28.4 kg/
m2) died of pulmonary distress on PoD 8 (Table 4).
Morbidity was significantly higher in the obese group (32.9%
[28/85] vs. 21.2% [36/170]; P = 0.041). Only grade II morbidities
were increased (14.1% [12/85] in obese patients vs. 1.8% [3/170]
in non-obese patients; P < 0.001), but no differences occurred in
Table 2 Preoperative characteristics and histopathological steatosis severity
Obese patients
BMI > 30 kg/m2 (n = 85)
Non-obese patients
BMI  30 kg/m2 (n = 170)
P-value
Median age (range), years 62.5 (24–83) 62.5 (15–84) 0.918
Male sex 41 (48.2%) 113 (66.5%) 0.005
Preoperative chemotherapy 15 (17.6%) 35 (20.6%) 0.577
Co-morbidities
Arterial hypertension 38 (44.7%) 64 (37.6%) 0.278
Diabetes 18 (21.2%) 28 (16.5%) 0.357
COPD 6 (7.1%) 15 (8.8%) 0.629
Cardiovascular disease 6 (7.1%) 10 (5.9%) 0.715
Steatosis
Absent (0%) 16 (18.9%) 62 (36.5%) 0.004
Mild (1–30%) 45 (52.9%) 101 (59.4%) 0.325
Moderate (31–60%) 20 (23.5%) 6 (3.5%) <0.001
Severe (>60%) 4 (4.7%) 1 (0.6%) 0.044
Liver function tests, median (range)
AST, U/l 26 (8–568) 26 (10–253) 0.849
ALT, U/l 27 (7–535) 23 (8–411) 0.154
GGT, U/l 69 (4–1229) 57.5 (5–1384) 0.799
Total bilirubin, mmol/l 11 (4–56) 11 (4–499) 0.252
PT, % 90 (43–100) 92 (63–110) 0.086
Creatinine, mmol/l 86 (48–168) 89 (40–259) 0.886
Liver function tests in cirrhotic patients, median (range) n = 17 n = 34
Albumin, g/l 40 (25–48) 41.4 (25.8–53.9) 0.391
Total bilirubin, mmol/l 14 (8–39) 12 (5–26) 0.163
PT, % 76.5 (50–110) 83 (63–110) 0.115
Ascites – 2 0.547
Encephalopathy – 3 0.542
Platelet count, 103/mm3 123.5 (63–279) 154 (47–315) 0.353
COPD, chronic pulmonary obstructive disease; AST, aspartate aminotranferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase;
PT, prothrombin time
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severe complications (grades III and IV). With regard to compli-
cation types, abdominal wall morbidities (abscess, haematoma or
wound dehiscence) were more frequent in obese patients (8.2%
[7/85] vs. 2.4% [4/170]; P = 0.046). A non-significant increase was
observed for infectious complications (18.8% [16/85] vs. 12.4%
[21/170]; P = 0.167). Liver-specific morbidity, such as liver
dysfunction, bile leak, portal vein thrombosis, ascites and abdomi-
nal collection, occurred at similar incidences in both groups.
In the 26 obese patients who underwent laparoscopic liver
resection (excluding patients who were converted to open resec-
tion), abdominal wall morbidity was low (one patient) and lower
than in obese patients who underwent open resection (10.1%
[6/59]; P = 0.431). These findings were similar to those in non-
obese patients. Moreover, this complication occurred in the early
part of the laparoscopic experience (2000) and no further cases
were subsequently observed.
Table 3 Intraoperative data
Surgical approach Obese patients
BMI > 30 kg/m2 (n = 85)
Non-obese patients
BMI  30 kg/m2 (n = 170)
P-value
Laparoscopy 28 (32.9%) 57 (33.5%) 0.925
Hand-assisted 4 (14.3%) 7 (12.3%) 0.797
Conversion 2 (7.1%) 3 (5.3%) 0.885
Vascular clamping
No clamping 28 (32.9%) 65 (38.2%) 0.408
Pedicle clamping 53 (62.4%) 97 (57.1%) 0.418
Total vascular exclusion 4 (4.7%) 8 (4.7%) 0.754
Blood loss, ml 300 (0–1500) 300 (0–2000) 0.367
Operative time, min 210 (60–360) 180 (80–420) 0.931
Blood transfusions 4 (4.7%) 9 (5.3%) 0.841
Plasma transfusions 1 (1.2%) 1 (0.6%) 1.000
Continuous variables are reported as median value (range)
Table 4 Overall postoperative morbidity, mortality and length of stay
Obese patients
BMI > 30 kg/m2 (n = 85)
Non-obese patients
BMI  30 kg/m2 (n = 170)
P-value
Mortality 2 (2.4%) 4 (2.4%) 0.603
Overall morbidity 28 (32.9%) 36 (21.2%) 0.041
Grade I 5 (5.9%) 4 (2.4%) 0.280
Grade II 12 (14.1%) 3 (1.8%) <0.001
Grade III (a/b) 6 (7.1%) (4/2) 17 (10.0%) (13/4) 0.440
Grade IV (a/b) 3 (3.5%) (3/0) 8 (4.7%) (9/0) 0.913
Liver dysfunction 4 (4.7%) 10 (5.9%) 0.923
Bile leak 2 (2.4%) 7 (4.1%) 0.719
Haemoperitoneum 2 (2.4%) 3 (1.8%) 0.873
Portal vein thrombosis 1 (1.2%) 1 (0.6%) 1.000
Intra-abdominal collection 3 (3.5%) 4 (2.4%) 0.892
Ascites 4 (4.7%) 5 (2.9%) 0.719
Pulmonary 6 (7.1%) 12 (7.1%) 0.576
Infectious 16 (18.8%) 21 (12.4%) 0.167
Abdominal wall morbiditya 7 (8.2%) 4 (2.4%) 0.046
Transient renal dysfunction 1 (1.2%) 1 (0.6%) 1.000
Cardiac arrhythmia 1 (1.2%) 2 (1.2%) 1.000
Reoperation 3 (3.5%) 6 (3.5%) 0.719
Hospital stay, median
(range), days
9 (2–50) 8 (2–115) 0.907
aAbdominal wall morbidity includes abscess, haematoma and wound dehiscence
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Outcomes in four subgroups were analysed separately. These
subgroups included: patients who underwent major hepatectomy;
patients with cirrhosis; patients with diabetes, and patients
with moderate or severe steatosis (Table 5). Results in these sub-
groups were similar to those for the whole series: mortality was
low and similar in obese and non-obese patients, whereas overall
morbidity tended to be higher in obese patients through all sub-
groups. Incidences of grade II complications were higher in obese
patients, with significant differences in cirrhotic and diabetic
patients (4/17 vs. 0/34 [P = 0.018] and 5/18 vs. 1/28 [P = 0.028],
respectively). Obesity was not associated with increased rates of
severe morbidity (grades III and IV) in any of the four subgroups.
When patients were stratified according to their BMI (<20,
20–25, 25–30 and >30 kg/m2), a progressive increase in overall
morbidity rates was observed (5.6% [1/18], 22.4% [17/76], 23.7%
[18/76] and 32.9% [28/85], respectively) (Fig. 1). Grade I compli-
cations increased from 0% (0/18) to 5.9% (5/85) and grade II
from 0% (0/18) to 14.1% (12/85). Grade III and IV morbidity
rates remained stable. Infectious complication rates progressively
increased (5.6% [1/18], 11.8% [9/76], 14.5% [11/76], and 18.8%
[16/85], respectively).
Among the obese patients classified according toWHO criteria,
those with a BMI of 35–40 kg/m2 (class II obesity,1 13 patients) or
>40 kg/m2 (class III obesity 1, five patients) did not have worse
outcomes. Both postoperative deaths occurred in patients with
BMIs of <35 kg/m2 (33.1 kg/m2 and 32.9 kg/m2). Morbidity rates,
both globally and when stratified according to the Clavien classi-
fication, did not increase. Among five morbidly obese patients
(BMI > 40 kg/m2), only one case of mild renal dysfunction
occurred, which was treated with diuretics.
Discussion
Increased surgical risk has been anticipated for obese patients
undergoing liver surgery because of associated co-morbidities,
underlying liver disease and technical difficulties.5–7,9–12 The
present series did not confirm this hypothesis and demonstrated
that liver surgery can be safely performed even in patients with a
BMI > 30 kg/m2. Overall morbidity was increased, but was related
to minor complications, especially abdominal wall issues. Severe
and liver-specific complications, such as liver failure and bile leak,
occurred at similar frequencies in obese and non-obese patients.
Even in patients with cirrhosis, mild or severe steatosis, diabetes
and those undergoing major hepatectomy, similar results were
observed. Obesity of WHO grades II and III1 was not associated
with increased surgical risk.
The impact of obesity on surgical outcomes is achieving
significant attention because the prevalence of this condition
is rapidly increasing worldwide.1 In our centre, about 12% of
patients who underwent liver surgery during the last 10 years were
Table 5 Morbidity and mortality subgroup analysis
Obese
patients
BMI > 30
kg/m2
Non-obese
patients
BMI  30
kg/m2
P-value
Major hepatectomy n = 42 n = 84
Mortality 2 4 1.000
Overall morbidity 18 29 0.362
Grade I 3 2 0.420
Grade II 6 3 0.059
Grade III 4 13 0.519
Grade IV 3 7 0.816
Cirrhotic patients (F4) n = 17 n = 34
Mortality 1 2 1.000
Overall morbidity 6 8 0.375
Grade I – 1 1.000
Grade II 4 – 0.018
Grade III 1 4 0.868
Grade IV – 1 1.000
Diabetic patients n = 18 n = 28
Mortality – 1 1.000
Overall morbidity 8 5 0.051
Grade I 1 – 0.391
Grade II 5 1 0.028
Grade III 1 1 1.000
Grade IV 1 2 1.000
Moderate/severe steatosis n = 24 n = 7
Mortality – – 1.000
Overall morbidity 8 1 0.615
Grade I 2 – 1.000
Grade II 4 – 0.550
Grade III 1 1 0.407
Grade IV 1 – 1.000
35
<20 20–25 25−30 >30
30
25
20
15
10
5
0
%
Mortality Overall
morbidity
Grade I Grade II Grade III Grade IV Infectious
morbidity
BMI, kg/m2:
Figure 1 Mortality and morbidity according to body mass index
(BMI). Patients were stratified into four groups on the basis of their
BMI: < 20 kg/m2 (n = 18); 20–25 kg/m2 (n = 76); 25–30 kg/m2 (n = 76),
and > 30 kg/m2 (n = 85)
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obese. This percentage reflects the prevalence of obesity in France,
but a significant increase is expected within a few years.3 Further-
more, obesity has been reported to be a risk factor for develop-
ment of primary liver tumours, such as liver adenoma and
HCC.8,36
Surgical outcomes in obese patients have been studied in dif-
ferent surgical fields. The largest available series, published by
Dindo et al.,24 compared 808 obese with about 5500 non-obese
patients undergoing elective general surgery. They reported no
difference between the two groups except for an increased rate of
wound infections in the obese group. Despite the large number of
included patients, only a minority underwent liver surgery. In fact,
the authors classified the surgical procedures into three groups,
with group C including oesophageal, rectal, pancreatic and liver
operations. Group C, when considered globally, included only 32
obese patients. Therefore, these conclusions cannot be generalized
to liver surgery. To date, only one paper has specifically focused on
liver surgery, but its definition of obesity was BMI > 25 kg/m2 and
only eight patients met the WHO definition (BMI > 30 kg/m2).18
The present paper is the first to specifically report on this topic
using standardized definitions of obesity that can be generalized
across Western countries.We decided to match patients in a case–
control fashion in order to limit the impact of confounding
factors on surgical outcomes. The main anticipated confounding
factors were associated co-morbidities such as cardiovascular and
pulmonary disease and diabetes, which are common in obese
patients and are known to negatively impact surgical out-
comes.5,6,24 The ASA score identifies the presence of associated
co-morbidities well and is a known independent predictor for
postoperative morbidity.19,24 By matching patients according to
their ASA scores, we eliminated differences among key
co-morbidities between the two groups and better analysed the
impact of obesity on surgical outcomes. Underlying liver paren-
chymal disease may represent a further factor influencing out-
comes. Steatosis and non-alcoholic fatty liver disease are common
in obese patients7,8 and are associated with worse postoperative
outcomes.7,9–12 This is why patients were matched for fibrosis, but
not for steatosis. As expected, steatosis was more common and
more severe in the obese group. Finally, a higher proportion of
female patients was observed in the obese group. This reflects the
higher prevalence of obesity among women.1 Similar data were
reported by Dindo et al.24 This difference between the two groups
should not influence the results of the present study because sex
usually does not impact on surgical outcomes.24,37,38
In obese patients, technical intraoperative difficulties are antici-
pated. Longer operative times and higher transfusion rates have
been observed in obese patients undergoing rectal19 and pancre-
atic surgery.22 Similar data were reported by Utsunomiya et al.18 in
overweight patients (BMI > 25 kg/m2) treated for recurrent HCC.
These differences were not confirmed by the present series. Only
operative time tended to be longer, but the difference was not
significant. Despite a higher degree of steatosis in obese patients,
bleeding risk was not increased, as was clearly depicted by similar
rates of blood loss, transfusion and need for pedicle clamping
between the two groups. Further, there was no significant differ-
ence in resection margins for malignant lesions, suggesting that
even oncological principles are not compromised in obese
patients.
The impact of obesity on postoperative morbidity is still
debated. Results of published papers are extremely heterogeneous:
some suggest there are no differences and others report a high
mortality rate and poor longterm outcomes in obese subjects.13–23
The large series reported by Dindo et al.24 apparently refuted these
differences, reporting similar morbidity rates in obese and non-
obese patients, except for wound infections. However, because the
study by Dindo et al.24 included few liver resections, its findings
cannot be generalized to this population. Prior to the present
study, only Utsunomiya et al.18 had analysed the impact of obesity
on liver surgery. These authors reported higher morbidity and
infection rates and lower survival in overweight patients(BMI >
25 kg/m2) undergoing repeat hepatectomy for recurrent HCC. In
the present series, obese patients had increased morbidity rates.
However, these reflected minor complications, typically related to
the abdominal wall. Liver-related morbidity, such as liver failure
and bile leak, and severe complications occurred at similar fre-
quencies in both groups. The same results were observed in
patients at increased risk as a result of the extent of liver resection
(major hepatectomies), co-morbidities (cirrhosis, diabetes) and
primary liver parenchymal disease (mild or severe steatosis).
Interestingly, morbidity rates progressively increased in line with
BMI. This reflected progressive increases in Clavien grade I and II
complications (typically infectious), whereas severe morbidity
remained stable. However, patients with WHO grade II and III
obesity1(BMI > 35 kg/m2) did not show an increase in morbidity
over patients with grade I obesity (BMI 30–35 kg/m2). Based on
these results, we can infer that obesity in patients undergoing liver
surgery is not associated with increased surgical risk and severe
complications. A strict patient selection policy based on liver
function, volume andASA score is mandatory and allows for good
outcomes in liver surgery, even in obese patients.
In obese patients, a further decrease in morbidity can be
achieved by using a laparoscopic approach. This was attempted in
about one-third of patients in both groups, and obesity did not
affect the success of a minimally invasive approach. Randomized
controlled trials comparing laparoscopic and open bariatric
operations demonstrated a significant reduction in abdominal
wall morbidity in the first group.39,40 Similar results were reported
in the present series: among obese patients, abdominal wall mor-
bidity was observed in only one patient undergoing laparoscopic
liver resection, but in 10% of patients undergoing open resection.
Moreover, as previously reported,31 technical refinements of our
laparoscopic technique allowed for a further reduction in abdomi-
nal wall morbidity and no more cases were observed in the later
years. According to the present findings, laparoscopic liver surgery
is feasible in obese patients and should be considered whenever
indications are consistent.
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The present results have some limitations. Firstly, although BMI
is the most common way to evaluate obesity, more accurate
indexes such as waist and hip circumferences or waist : hip ratio
may better integrate the proportion of muscle mass when identi-
fying obese patients.1,3 Secondly, few patients with grade III
obesity (n = 5) were present in our database, reflecting the low
occurrence of grade III obesity in Europe.3 Therefore, the gener-
alizability of these findings to morbidly obese patients may be
limited. Finally, increased risk for late complications such as
embolism and incisional hernia can be expected in obese patients.
Our retrospective analysis was focused on in-hospital morbidity
and late complications may be underestimated. Prospective
studies are needed to better assess these issues. Despite these limi-
tations, our data accurately depict the outcomes of liver surgery in
obese patients because of the large number of patients included
and the case–control design in a population that cannot be
randomized.
In conclusion, obesity should not be considered a risk factor for
liver surgery. Obesity was not associated with significantly longer
operative time or increased bleeding, and oncological principles
were upheld. Laparoscopic liver surgery was equally feasible in
obese patients. Higher morbidity rates were observed in obese
patients, but were mainly related to minor complications, such as
abdominal wall infections. Liver-specific morbidity and severe
complications were not related to BMI. Good patient selection
in terms of liver function, liver volume and associated
co-morbidities is the key to good outcomes after liver surgery,
independent of BMI.
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